Trial Profile
The effect of Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, after cardiac surgery
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2017
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary) ; Diuretics
- Indications Heart failure
- Focus Pharmacodynamics
- 28 Jun 2017 Status changed from recruiting to completed.
- 06 Aug 2013 New trial record